LAEVOROC ONCOLOGY
Laevoroc Oncology is to leverage word-class technologies, extensive R&D, and commercial experience to approach innovation in cancer therapeutics in a way that combines the pragmatic with the visionary.
LAEVOROC ONCOLOGY
Social Links:
Industry:
Medical Therapeutics
Founded:
2019-01-01
Address:
Hünenberg, Zug, Switzerland
Country:
Switzerland
Website Url:
http://www.laevoroc.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
1.1 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Font API Apple Mobile Web Clips Icon WordPress Content Delivery Network Font Awesome Wordpress Plugins Sitelinks Search Box
Similar Organizations
Aulos Bioscience
Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics.
Scholar Rock
Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.
Slingshot Biosciences
Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics.
Theolytics
Theolytics is a pre-clinical stage biotechnology company developing next-generation oncolytic viral therapies.
Vetsource
Vetsource provides comprehensive solutions to those who care for pets - veterinarians and pet owners.
Current Employees Featured
Founder
Official Site Inspections
http://www.laevoroc.com Semrush global rank: 5.48 M Semrush visits lastest month: 1.56 K
- Host name: 99.0.153.160.host.secureserver.net
- IP address: 160.153.0.99
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "Laevoroc Oncology"
LAEVOROC Oncology AG
Laevoroc Neuro-Oncology is the core of our company and will build a pipeline of innovative drugs addressing brain cancers. Right now, we are progressing LR 02 ( a highly selective and potent …See details»
Laevoroc Oncology AG – Swiss Biotech
Founded in 2019, Laevoroc is a privately-owned, Swiss oncology group of companies with a purpose to deliver next-generation and game-changing immuno-oncology therapies to patients living with cancer. …See details»
Laevoroc Oncology - Crunchbase Company Profile & Funding
Laevoroc Oncology is to leverage word-class technologies, extensive R&D, and experience to approach innovation in cancer therapeutics. View contacts for Laevoroc Oncology to access …See details»
Laevoroc Oncology Launches WithThree-Pronged Strategy
Mar 18, 2022 · Laevoroc Chemotherapy will develop a new oral gemcitabine prodrug, LR 06B, aiming to make a positive impact on health equity and quality of care for cancer patients …See details»
Laevoroc Oncology Emerges from stealth mode announcing seed...
Zug, Switzerland, 11 May 2021: Laevoroc Oncology (‘Laevoroc’ or ‘the company’), a privately owned, Swiss oncology development group of companies, launched today announcing …See details»
Helix Biopharma Corp. Enters into Non-Binding Letter of Intent to ...
Nov 13, 2024 · Laevoroc Immunology’s asset is a novel, highly potent and selective inhibitor of purine nucleoside phosphorylase (PNP) in preclinical development for the treatment of …See details»
Thomas Mehrling - Founder-ceo At Laevoroc at …
Feb 1, 2019 · Thomas Mehrling is the Founder-CEO of Laevoroc. Previously, Thomas served as the Chairman Of The Board Of Directors at SynDermix AG and as the Managing Director and later CEO at Mundipharma EDO GmbH.See details»
Laevoroc Oncology Company Profile - Office Locations ... - Craft
Laevoroc Oncology AG is an oncology development group of companies providing cancer therapeutic technology and developing drugs to treat the condition. The company pursues an …See details»
Laevoroc - LinkedIn
Laevoroc | 297 followers on LinkedIn. Revolutionizing treatment for leukaemia relapse. | Spearheading the development of a novel PNP inhibitor poised to revolutionize treatment for …See details»
Helix Biopharma Corp. Enters into Non-Binding Letter of Intent to ...
Nov 13, 2024 · Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0 20241113_Laevoroc LOI_Final ”) (“Helix” or the “Company), a clinical …See details»
Laevoroc Immunology Announces FDA Orphan Drug Designation
ZUG, Switzerland, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Laevoroc Immunology (‘Laevoroc’ or ‘the company’), a privately-owned, Swiss oncology development company, today announced …See details»
Over USD 1.1 million seed capital for Laevoroc Oncology
May 21, 2021 · Two years following its foundation, the company (formerly known as TNT-Medical Corporation AG) founded by Thomas Mehrling and Davide Guggi, who have over 40 years …See details»
Laevoroc Oncology Launches WithThree-Pronged Strategy
May 24, 2021 · In Vivo interview with our CEO, Thomas Mehrling, where he presented Laevoroc Oncology’s three-pronged strategy to off-set risk and provide greater choice to future partners …See details»
Laevoroc Oncology publishes preclinical data on leukemia treatment
Dec 8, 2022 · Laevoroc Oncology (‘Laevoroc’ or ‘the company’), a privately-owned, Swiss oncology development company, announced today the publication of key preclinical data …See details»
Laevoroc Chemotherapy Will Develop a New Oral Gemcitabine …
The agreement succeeds a collaboration agreement between the two companies and marks the evolution of Laevoroc's former wholly-owned subsidiary, Laevoroc Chemotherapy, into a joint …See details»
Laevoroc Immunology: FDA Orphan Drug Designation for …
Feb 28, 2023 · Laevoroc Immunology (‘Laevoroc’ or ‘the company’), a privately-owned, Swiss oncology development company, today announced that the U.S. Food and Drug …See details»
Laevoroc Oncology Launches WithThree-Pronged Strategy
Jul 7, 2021 · Laevoroc is pursuing an asset-centric business model with three subsidiaries (chemotherapy, immunology and neuro-oncology) covering a pipeline that spans breakthrough …See details»
Laeverdoc (fka TNT Medical) - VentureRadar
Website: http://laevoroc.com/ Develops innovative cancer therapeutics through three subsidiaries focusing on chemotherapy, immunology, and neuro-oncology, targeting pancreatic, ovarian, …See details»
Helix Biopharma signs LOI to acquire Laevoroc Group's oncology …
Helix BioPharma (TSX:HBP:CA) on Wednesday said it has entered into a non-binding letter of intent (LOI) to acquire the oncology assets of Laevoroc Chemotherapy and Laevoroc …See details»